Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18-45 years: Follow-up through Month 48 in a Phase III randomized study
【期刊】:Hum Vaccin Immunother 【年、卷、期、起止页码】:2014 Nov 1:e36117. 【全文链接】:http://www.tandfonline.com/doi/abs/10.4161/hv.36117?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%3dpubmed